Soleno Therapeutics (SLNO) Interest Coverage Ratio (2013 - 2026)
Soleno Therapeutics (SLNO) posted quarterly Interest Coverage Ratio of 1.15 for Q1 2026, up 103.42% year-over-year from 0.56 in Q1 2025, and down 96.09% quarter-over-quarter from 29.34 in Q4 2025.
Soleno Therapeutics (SLNO) Interest Coverage Ratio (2013 - 2026) Analysis & Trends
Soleno Therapeutics (SLNO) has reported Interest Coverage Ratio for 13 consecutive years, with 1.15 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Coverage Ratio rose 103.42% year-over-year to 1.15; the TTM figure through Mar 2026 stood at 3.17 (up 102.33% YoY), while the FY2025 annual figure was 0.12, up 105.24% from the prior year.
- Interest Coverage Ratio eased to 1.15 in Q1 2026 per SLNO's latest filing, from 29.34 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 3477.41 in Q4 2024 and bottomed at 16208.65 in Q2 2023.
- Historically, Interest Coverage Ratio has averaged 767.34 across 5 years, with a median of 0.35 in 2024.
- Annual changes were most pronounced in 2023 — Interest Coverage Ratio plunged 183502.21% — and 2024, when it soared 2024.95%.
- Soleno Therapeutics' Interest Coverage Ratio stood at 0.1 in 2022, then slumped by 183502.21% to 180.65 in 2023, then jumped by 2024.95% to 3477.41 in 2024, then slumped by 99.16% to 29.34 in 2025, then tumbled by 96.09% to 1.15 in 2026.
- Business Quant data shows SLNO's Interest Coverage Ratio at 1.15 in Q1 2026, 29.34 in Q4 2025, and 0.19 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Soleno Therapeutics | 2.74 Bn | 2.49 Bn | 93.41 Mn | 1.15 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.15 |
| Dec 31, 2025 | 29.34 |
| Sep 30, 2025 | 0.19 |
| Jun 30, 2025 | -0.04 |
| Mar 31, 2025 | -33.61 |
| Dec 31, 2024 | 3,477.41 |
| Sep 30, 2024 | -0.83 |
| Jun 30, 2024 | -0.35 |
| Mar 31, 2024 | -0.30 |
| Dec 31, 2023 | -180.65 |
| Sep 30, 2023 | -0.22 |
| Jun 30, 2023 | -16,208.65 |
| Mar 31, 2023 | -71.17 |
| Dec 31, 2022 | -0.10 |
| Sep 30, 2022 | -25.04 |
| Jun 30, 2022 | -19.15 |
| Mar 31, 2022 | -12.83 |
| Sep 30, 2021 | -167.08 |
| Jun 30, 2021 | -18.06 |
| Dec 31, 2020 | -0.19 |